These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 8251109)
1. The domestic drug regulatory process: why time is of the essence. Katz R Epilepsy Res Suppl; 1993; 10():91-106. PubMed ID: 8251109 [No Abstract] [Full Text] [Related]
2. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods. Browne TR Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105 [No Abstract] [Full Text] [Related]
3. Study population selection. Treiman DM Epilepsy Res Suppl; 1993; 10():125-35. PubMed ID: 8251088 [No Abstract] [Full Text] [Related]
4. Sources of variability in clinical trials of new drugs for epilepsy. Leppik IE Epilepsy Res Suppl; 1993; 10():157-66. PubMed ID: 8251091 [No Abstract] [Full Text] [Related]
5. External influences on protocol design. Spilker B Epilepsy Res Suppl; 1993; 10():115-24. PubMed ID: 8251087 [No Abstract] [Full Text] [Related]
6. Protocol design. Wilensky AJ Epilepsy Res Suppl; 1993; 10():107-13. PubMed ID: 8251086 [No Abstract] [Full Text] [Related]
7. European investigational antiepilepsy drug trials. Sussman NM Epilepsy Res Suppl; 1993; 10():149-55. PubMed ID: 8251090 [No Abstract] [Full Text] [Related]
8. Preparing for an FDA audit. Barnes D Epilepsy Res Suppl; 1993; 10():245-50. PubMed ID: 8251103 [No Abstract] [Full Text] [Related]
10. The role of the pharmacist in investigational AED trials. Graves NM Epilepsy Res Suppl; 1993; 10():201-9. PubMed ID: 8251098 [No Abstract] [Full Text] [Related]
11. Patient recruitment and compliance issues in clinical trials. Cramer JA Epilepsy Res Suppl; 1993; 10():211-22. PubMed ID: 8251099 [No Abstract] [Full Text] [Related]
12. Obstacles encountered in designing antiepileptic drug trials. French JA Epilepsy Res Suppl; 1993; 10():81-9. PubMed ID: 8251107 [No Abstract] [Full Text] [Related]
13. Role of the Institutional Review Board in clinical trials. Skolnick BE Epilepsy Res Suppl; 1993; 10():193-200. PubMed ID: 8251097 [No Abstract] [Full Text] [Related]
14. Accelerated approval and oncology drug development timelines. Lanthier ML; Sridhara R; Johnson JR; Farrell A; Keegan P; Justice R; Pazdur R J Clin Oncol; 2010 May; 28(14):e226-7; author reply e228. PubMed ID: 20194846 [No Abstract] [Full Text] [Related]
15. Science and regulatory rituals associated with the drug development process. Versteegh LR Food Drug Law J; 1997; 52(2):155-61. PubMed ID: 10557552 [No Abstract] [Full Text] [Related]
16. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process. Binzak BA Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592 [No Abstract] [Full Text] [Related]
17. Progress and deficiencies in the registration of clinical trials. Wood AJ N Engl J Med; 2009 Feb; 360(8):824-30. PubMed ID: 19228628 [No Abstract] [Full Text] [Related]
18. Moment of reckoning. Wadman M Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154 [No Abstract] [Full Text] [Related]
19. Trouble at the office. Allison M Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797 [No Abstract] [Full Text] [Related]
20. Clinical development of drugs for epilepsy: a review of approaches in the United States and Europe. Porter RJ; Baulac M; Nohria V Epilepsy Res; 2010 May; 89(2-3):163-75. PubMed ID: 20347575 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]